Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. 2010

Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
Invenio Therapeutics, Cleveland, Ohio, USA.

The identification of agents that preferentially kill cancer cells while protecting normal cells offers the potential to overcome toxicities found in many existing chemotherapeutic agents. Because p53 is frequently inactivated in cancer, agents that preferentially kill p53-null cells and protect wild-type p53-expressing cells are highly desirable chemotherapeutic agents. By using pairs of isogenic colon cancer cell lines that differ only in p53 expression (RKO and HCT116), securinine was found to exhibit these properties. Securinine (30 microM) induces apoptosis in 73% of p53-null HCT116 cells (LD(50) 17.5 microM) as opposed to 17.6% of HCT116 parental cells (LD(50) 50 microM) at 72 h after treatment. The mechanism of securinine-mediated death in p53-deficient cells involves the induction of the p53 family member, p73. Interestingly, the proapoptotic protein p73 is down-regulated in colon cancer cells expressing p53. This differential regulation of p73 in a p53-dependent fashion reveals a novel pathway for preferentially targeting cancer cells. In contrast to p53-deficient cells, cells expressing p53 are protected from cell death through the p53-mediated up-regulation of p21. These studies reveal a novel approach to specifically target colon cancer cells lacking p53 as well as identify a novel clinically relevant pathway to selectively induce p73 in p53-null cells.

UI MeSH Term Description Entries
D007783 Lactones Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactone
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D010880 Piperidines A family of hexahydropyridines.
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D006572 Heterocyclic Compounds, Bridged-Ring A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms. Bridged-Ring Heterocyclic Compounds,Bridged Ring Heterocyclic Compounds,Compounds, Bridged-Ring Heterocyclic,Heterocyclic Compounds, Bridged Ring
D006576 Heterocyclic Compounds, 4 or More Rings A class of heterocyclic compounds that include four or more fused rings. Both aromatic or non-aromatic ring structures are included in this category. Heterocyclic Compounds with 4 or More Rings,Five Ring Heterocyclic Compounds,Four Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Five-Ring,Fused Heterocyclic Compounds, Four-Ring,Heterocyclic Compounds with Four or More Rings,Heterocyclic Compounds, 4-Ring,Heterocyclic Compounds, 5-Ring,Heterocyclic Cpds, 4 Ring,Heterocyclic Cpds, 4 or More Rings,Heterocyclic Cpds, 5 Ring,4-Ring Heterocyclic Compounds,5-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Five Ring,Fused Heterocyclic Compounds, Four Ring,Heterocyclic Compounds, 4 Ring,Heterocyclic Compounds, 5 Ring

Related Publications

Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
November 2008, Cancer research,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
September 2013, Life sciences,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
July 2007, Biochemical and biophysical research communications,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
January 2011, Apoptosis : an international journal on programmed cell death,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
September 2018, Oncology letters,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
January 2022, Nutrition and cancer,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
October 2016, Molecular medicine reports,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
July 2015, Cancer letters,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
September 2000, International journal of oncology,
Sonia Rana, and Kalpana Gupta, and Jose Gomez, and Shigemi Matsuyama, and Amitabha Chakrabarti, and Munna L Agarwal, and Anju Agarwal, and Mukesh K Agarwal, and David N Wald
October 2005, International journal of cancer,
Copied contents to your clipboard!